信达生物-话题@MedSci

#信达生物#

29篇内容 | 1984人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1465464, encodeId=45061465464a8, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=微芯生物与信达生物宣布合作开展晚期结直肠癌联合治疗的临床评估, objectType=article, longId=160430, objectId=d8d71604300d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d71604300d, replyNumber=0, likeNumber=65, createdTime=2019-02-20, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d71604300d, moduleTitle=微芯生物与信达生物宣布合作开展晚期结直肠癌联合治疗的临床评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d71604300d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465463, encodeId=3d441465463a2, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物和礼来合作的双特异性抗体临床试验获NMPA批准, objectType=article, longId=159800, objectId=f33015980063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f33015980063, replyNumber=0, likeNumber=46, createdTime=2019-02-13, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f33015980063, moduleTitle=信达生物和礼来合作的双特异性抗体临床试验获NMPA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f33015980063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465462, encodeId=700e146546299, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, objectType=article, longId=158309, objectId=2e6815830948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6815830948, replyNumber=0, likeNumber=85, createdTime=2019-01-19, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6815830948, moduleTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6815830948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465461, encodeId=f7b414654612f, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物宣布抗CD47单抗 I 期临床研究完成首例患者给药, objectType=article, longId=158139, objectId=c049158139f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c049158139f5, replyNumber=0, likeNumber=70, createdTime=2019-01-17, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c049158139f5, moduleTitle=信达生物宣布抗CD47单抗 I 期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c049158139f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465460, encodeId=8b96146546074, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估, objectType=article, longId=154784, objectId=d290154e847a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d290154e847a, replyNumber=0, likeNumber=85, createdTime=2018-12-02, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d290154e847a, moduleTitle=信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d290154e847a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465459, encodeId=ddbf14654594a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物在2018年亚洲肺癌大会(ACLC)公布信迪利单抗临床研究结果, objectType=article, longId=153240, objectId=4520153240ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4520153240ae, replyNumber=0, likeNumber=94, createdTime=2018-11-12, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4520153240ae, moduleTitle=信达生物在2018年亚洲肺癌大会(ACLC)公布信迪利单抗临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4520153240ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465458, encodeId=89dd146545806, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物的CD47单抗新药IBI188中国IND申报成功, objectType=article, longId=148593, objectId=203a14859380, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=203a14859380, replyNumber=0, likeNumber=55, createdTime=2018-09-12, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=203a14859380, moduleTitle=信达生物的CD47单抗新药IBI188中国IND申报成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=203a14859380)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465457, encodeId=55c7146545e41, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物PD-1单抗霍奇金淋巴瘤关键II期研究数据公布：客观缓解率近80%, objectType=article, longId=138399, objectId=5e2d138399e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e2d138399e0, replyNumber=0, likeNumber=71, createdTime=2018-05-19, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e2d138399e0, moduleTitle=信达生物PD-1单抗霍奇金淋巴瘤关键II期研究数据公布：客观缓解率近80%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e2d138399e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465456, encodeId=c1d91465456ef, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=礼来要拿4亿美元与信达生物合作开发抗肿瘤药, objectType=article, longId=48578, objectId=b649485e899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b649485e899, replyNumber=0, likeNumber=73, createdTime=2015-03-26, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b649485e899, moduleTitle=礼来要拿4亿美元与信达生物合作开发抗肿瘤药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b649485e899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465455, encodeId=9a0b146545581, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=单抗新药开发公司信达生物获1亿美元C轮融资, objectType=article, longId=46826, objectId=1a12468266b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a12468266b, replyNumber=0, likeNumber=57, createdTime=2015-02-09, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a12468266b, moduleTitle=单抗新药开发公司信达生物获1亿美元C轮融资, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a12468266b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

信达生物

2020-05-29

yytms (审核中...)

前往app查看评论内容

#信达生物#

微芯生物与信达生物宣布合作开展晚期结直肠癌联合治疗的临床评估

2019-02-20

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物和礼来合作的双特异性抗体临床试验获NMPA批准

2019-02-13

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药

2019-01-19

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物宣布抗CD47单抗 I 期临床研究完成首例患者给药

2019-01-17

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估

2018-12-02

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物在2018年亚洲肺癌大会(ACLC)公布信迪利单抗临床研究结果

2018-11-12

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物的CD47单抗新药IBI188中国IND申报成功

2018-09-12

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物PD-1单抗霍奇金淋巴瘤关键II期研究数据公布：客观缓解率近80%

2018-05-19

yytms (审核中...)

前往app查看评论内容

#信达生物#

礼来要拿4亿美元与信达生物合作开发抗肿瘤药

2015-03-26

yytms (审核中...)

前往app查看评论内容

#信达生物#

单抗新药开发公司信达生物获1亿美元C轮融资

2015-02-09

科室
- - 订阅+
  - 更多科室
工具
服务